Reuters logo
BRIEF-Aveo Pharmaceuticals- Tivo-3 study will continue as planned without modification
October 5, 2017 / 9:38 PM / 2 months ago

BRIEF-Aveo Pharmaceuticals- Tivo-3 study will continue as planned without modification

Oct 5 (Reuters) - Aveo Pharmaceuticals Inc

* Aveo Pharmaceuticals Inc - ‍announces completion of Tivo-3 study futility analysis with no changes to study protocol​

* Aveo Pharmaceuticals Inc - ‍study will continue as planned without modification.​

* Aveo - ‍analysis did not allow for early stopping due to efficacy to assure adequate follow-up for key secondary endpoint of overall survival​

* Aveo - ‍continues to expect Tivo-3 to read out in Q1 of 2018​

* Aveo Pharmaceuticals Inc - ‍expansion portion of trial is expected to enroll an additional 20 subjects​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below